
It's Not Just Rates Favoring Pharma, Med Plays

By Stuart Chaussee
About this article:
It's no mystery that pharmaceutical stocks tend to do better in a rising interest rate environment. TheStreet.com Staff Reporter Gregg Greenberg gave details of the outperformance in his article, "The Case for Drug Stocks." One extreme example of outperformance he cited was in 1994, "when the Fed aggressively raised overnight lending rates from 3% to 6% in about a year's time. During that period the pharma index rose over 25% compared to a mere 2% gain for the S&P 500." Few economists, I imagine, would make a case that the Fed will raise rates aggressively over the coming year, but most now predict rates rising at some point in 2004.
Whether or not interest rates rise significantly from here will little affect my attraction to both large-cap drug and medical-supply stocks. As a value investor, both of these industries appeal to me. They offer above-average dividend yields and...

Or, call us at 1-866-321-TSCM (8726) Monday-Friday, 8 a.m.-6 p.m. ET.
Outside the U.S. and in Canada, call 1-212-321-5200.
|
|
|

 |

If you decide to subscribe and you're not completely satisfied with TheStreet.com RealMoney, just call us within the first 30 days of your subscription and we'll refund your full annual subscription price — guaranteed.
|
|
|
|
|
If you choose a 14-day free trial of RealMoney and you do NOT call to cancel within those 14 days, you will pay $129.95 — a $100 savings off the regular annual subscription price of $229.95. Unless you cancel before the end of that year, your subscription will automatically renew for another year at the then-current subscription price.
Offer applies only to new annual subscriptions, and is subject to change at any time. Void where prohibited.
If you choose a monthly subscription, you pay $34.95 per month. You will be notified if the current monthly rate of $34.95 changes at any time in the future.
TheStreet.com is a publisher. None of the contributors or their affiliates will provide you with personally tailored advice concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. From time to time, any or all of the contributors or their affiliates may hold positions in securities mentioned and they may trade for their own accounts. In cases where the position is held at the time of publication, appropriate disclosure is made.
© TheStreet.com, Inc., 14 Wall Street, 15th Floor, New York, NY 10005.
|